Matches in Nanopublications for { ?s ?p "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP981188.RAZJRA-PEb4Bk_h2vgsAw7TlSdYX3_y2Flm7IY2LeGhg4130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP981188.RAZJRA-PEb4Bk_h2vgsAw7TlSdYX3_y2Flm7IY2LeGhg4130_provenance.
- NP418574.RAXxBLFBtukwEQfejWjW24OtvspiJZCgwtERy1pKiw-QU130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418574.RAXxBLFBtukwEQfejWjW24OtvspiJZCgwtERy1pKiw-QU130_provenance.
- NP418576.RAWiEOOpcJjpO9vmXHtkOYq8rUc9KTZ7TaeGfN3aeqX-k130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418576.RAWiEOOpcJjpO9vmXHtkOYq8rUc9KTZ7TaeGfN3aeqX-k130_provenance.
- assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP334239.RAzEhvZqxOF0Kq4TkLlHLlF9SPSIXhGMwDUQA4GJtWVcM130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334239.RAzEhvZqxOF0Kq4TkLlHLlF9SPSIXhGMwDUQA4GJtWVcM130_provenance.
- NP334315.RAPrQFqqK3MZB6YUvnLjh7havmTqNJ-yu7kA1_bmKkv5Y130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334315.RAPrQFqqK3MZB6YUvnLjh7havmTqNJ-yu7kA1_bmKkv5Y130_provenance.
- NP981112.RA9-NXEXcSlCrGuC1vR4Ptx_1HmlAfZCSPamZp1rWEGHU130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP981112.RA9-NXEXcSlCrGuC1vR4Ptx_1HmlAfZCSPamZp1rWEGHU130_provenance.
- NP418573.RAE2FFABlMYZB6L6j9jvF1rO7o_MoHsf2IZWOcLcsZjk0130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418573.RAE2FFABlMYZB6L6j9jvF1rO7o_MoHsf2IZWOcLcsZjk0130_provenance.
- NP418575.RA6oyS4iCt2gVMgQAzuldOjjSaT0lnXSOd8VDfxvOOugs130_assertion description "[We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418575.RA6oyS4iCt2gVMgQAzuldOjjSaT0lnXSOd8VDfxvOOugs130_provenance.